期刊文献+

乳腺癌ER、PR和CerbB-2免疫组化对照芯片制作及其应用 被引量:1

下载PDF
导出
摘要 目的:应用组织芯片原理手工制作乳腺癌雌激素受体(ER)、孕激素受体(PR)和原癌基因CerbB-2免疫组化对照芯片。方法:选取ER、PR、CerbB-2免疫组化表达水平为-、+、++和+++的乳腺癌标本和相应的组织蜡块,使用自制的组织芯片采样器和改良的简易组织芯片制作方法制成组织芯片蜡块,经过连续切片获得对照芯片,每张对照芯片包含4个组织芯点位,依次为阴性对照和3个等级表达阳性对照。将常规工作中测试片裱贴在对照芯片旁边,同时进行免疫组化EnVision染色。结果:乳腺癌ER、PR、CerbB-2免疫组化染色结果能明确地在对照芯片中找到参照,测试组织是否阳性有了明确的对照。结论:乳腺癌ER、PR、CerbB-2免疫组化染色中设立等级对照十分必要,手工自制对照芯片方法简单,实用性强。
出处 《温州医学院学报》 CAS 2012年第4期361-363,共3页 Journal of Wenzhou Medical College
  • 相关文献

参考文献7

二级参考文献50

  • 1姚根有,陈培辉,来茂德,洪莉英,杨加珞.乳腺癌神经内分泌细胞免疫细胞化学的研究[J].中国组织化学与细胞化学杂志,1995,4(3):306-309. 被引量:5
  • 2张凡,张九鸿,段彩霞,王建云,成日青.Ki-67、VEGF、CD34表达与病理类型相关性的研究[J].河北北方学院学报(医学版),2006,23(6):1-5. 被引量:11
  • 3周才明,黎绍基,何健标.乳腺癌淋巴结转移与ER,PR,Ki67,p53表达的相关分析及临床意义[J].广东医学,2007,28(4):510-512. 被引量:12
  • 4Tavassoli FA, Scares J. Myoepithelial lesions. In; Tavassoli FA, Devileep. eds World Health Organization Classification of Tumours. In: WHO, ed Pathology and genetics of tumours of the breast and female genital organs [M]. Lyon: IARC Press,2003.
  • 5Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma. A repreoducibility study [ J ]. Cancer, 1994,73 : 2765.
  • 6Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen andproensterone receptor status in the major racial/ethaic groups [ J]. Breast cancer res treat,2002,74(3) :199.
  • 7Hayes DF, Yamauchi H, Broadwater G, et al. Circulating Her-2/erbB-2/ e-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B study 8662[J]. Clin Cancer Res,2001,7(9) :2703.
  • 8Elledge RM, Green S, Ciocca D, et al. Her-2 expression and response to tamoxifen in estrogen positive breast cancer. A southwest oncology Group Study[J]. Clin Cancer Research, 1998,4(1) :7.
  • 9Zadrozny M, Smolarz B, Romanowicz M, et al. Genetic analysis of HER-2/ neu gene amplification in paraffin embedded tumor tissue in women with breast caneer[J].Pol J Pathol,2002,53(4) :189.
  • 10Zhou D, Dattifora H, et al. Association of Multiple Copies of the C-erbB-2 oncogene with Spead of Breast Cancer[ J ]. CancerRes, 1987,47 (22) : 6123.

共引文献68

同被引文献14

  • 1Olshen AB, Venkatraman ES, Lucito R,et al. Circular bina-ry segmentation for the analysis of array-based DNA copynumber data[J]. Biostatistics, 2004,5(4): 557-572.
  • 2Matta A, Siu KW, Ralhan R. 14-3-3 zeta as novel moleculartarget for cancer therapy [J]. Expert Opin Ther Targets, 2012,16(5):515-523.
  • 3Wiedemeyer R, Brennan C,Hefferaan TP, et al. Feedbackcircuit among INK4 tumor suppressors constrains humanglioblastoma development^J]. Cancer Cell, 2008, 13(4): 355-364.
  • 4Shin S, Bose DG, Ingle JN, et al. Rcl is a novel ETV1/ER81target gene upregulated in breast tumors [J]. J Cell Biochem,2008,105(3): 866-874.
  • 5Dupouy C, Zhang C, Padilla A, et al. Probing the active siteof the deoxynucleotide N-hydrolase Rcl encoded by the ratgene c6orfl08[J]. J Biol Chem, 2010, 285(53): 41806-41814.
  • 6Lee KH, Choi EY,Kim MK, et al. Regulation of hepatocytegrowth factor-mediated urokinase plasminogen activatorse-cretion by MEK/ERX activation inhuman stomach cancercell lines[J]. Exp Mol Med, 2006, 38(1): 27-35.
  • 7Guo K, Liu Y,Zhou H, et al. Involvement of protein kinaseC p-extracellular signal-regulating kinasel/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation inhepatocellular carcinoma cell motility and invasion[J]. Can-cer Sci, 2008, 99(3): 486-496.
  • 8Bajpai U, Sharma R,Kausar T, et al. Clinical significanceof 14-3-3 zeta in human esophageal cancer[J]. Int J BiolMarker, 2007, 23(4): 231-237.
  • 9Bergamaschi A,Christensen BL,Katzenellenbogen BS. Re-versal of endocrine resistance in breast cancer: interrelation-ships among 14-3-3zeta, FOXM1, and a gene signature as-sociated with mitosisfJ]. Breast Cancer Res, 2011,13(3):R70.
  • 10Cheng L,Wang P,Yang S, et al. Identification of geneswith a correlation between copy number and expression ingastric cancer[J]. BMC Med Genomics, 2012, 5(1): 14.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部